BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 26673227)

  • 1. Xanthine oxidoreductase activity assay in tissues using stable isotope-labeled substrate and liquid chromatography high-resolution mass spectrometry.
    Murase T; Nampei M; Oka M; Ashizawa N; Matsumoto K; Miyachi A; Nakamura T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Jan; 1008():189-197. PubMed ID: 26673227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A highly sensitive assay for xanthine oxidoreductase activity using a combination of [(13) C2 ,(15) N2 ]xanthine and liquid chromatography/triple quadrupole mass spectrometry.
    Murase T; Oka M; Nampei M; Miyachi A; Nakamura T
    J Labelled Comp Radiopharm; 2016 May; 59(5):214-20. PubMed ID: 27006202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A highly sensitive assay of human plasma xanthine oxidoreductase activity using stable isotope-labeled xanthine and LC/TQMS.
    Murase T; Nampei M; Oka M; Miyachi A; Nakamura T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Dec; 1039():51-58. PubMed ID: 27816314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xanthine oxidoreductase activity is correlated with insulin resistance and subclinical inflammation in young humans.
    Washio KW; Kusunoki Y; Murase T; Nakamura T; Osugi K; Ohigashi M; Sukenaga T; Ochi F; Matsuo T; Katsuno T; Moriwaki Y; Yamamoto T; Namba M; Koyama H
    Metabolism; 2017 May; 70():51-56. PubMed ID: 28403945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Independent association of plasma xanthine oxidoreductase activity with serum uric acid level based on stable isotope-labeled xanthine and liquid chromatography/triple quadrupole mass spectrometry: MedCity21 health examination registry.
    Kurajoh M; Fukumoto S; Emoto M; Murase T; Nakamura T; Ishihara T; Go H; Yamamoto K; Nakatani S; Tsuda A; Yamada S; Morioka T; Mori K; Imanishi Y; Inaba M
    Clin Chem Lab Med; 2020 Apr; 58(5):780-786. PubMed ID: 31085741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Xanthine oxidoreductase activity is correlated with hepatic steatosis.
    Yagi C; Kusunoki Y; Tsunoda T; Murase T; Nakamura T; Osugi K; Ohigashi M; Morimoto A; Miyoshi A; Kakutani-Hatayama M; Kosaka-Hamamoto K; Kadoya M; Konishi K; Shoji T; Koyama H
    Sci Rep; 2022 Jul; 12(1):12282. PubMed ID: 35854080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice.
    Nakamura T; Murase T; Nampei M; Morimoto N; Ashizawa N; Iwanaga T; Sakamoto R
    Eur J Pharmacol; 2016 Jun; 780():224-31. PubMed ID: 27038523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Xanthine Oxidoreductase Activity as a Novel Biomarker of Metabolic Disorders in a General Population.
    Furuhashi M; Matsumoto M; Tanaka M; Moniwa N; Murase T; Nakamura T; Ohnishi H; Saitoh S; Shimamoto K; Miura T
    Circ J; 2018 Jun; 82(7):1892-1899. PubMed ID: 29643318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected high plasma xanthine oxidoreductase activity in female subjects with low levels of uric acid.
    Furuhashi M; Mori K; Tanaka M; Maeda T; Matsumoto M; Murase T; Nakamura T; Koyama M; Moniwa N; Ohnishi H; Saitoh S; Shimamoto K; Miura T
    Endocr J; 2018 Nov; 65(11):1083-1092. PubMed ID: 30068899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of allopurinol on uric acid concentrations, xanthine oxidoreductase activity and oxidative stress in broiler chickens.
    Carro MD; Falkenstein E; Radke WJ; Klandorf H
    Comp Biochem Physiol C Toxicol Pharmacol; 2010 Jan; 151(1):12-7. PubMed ID: 19654053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Xanthine oxidoreductase activity is associated with serum uric acid and glycemic control in hemodialysis patients.
    Nakatani A; Nakatani S; Ishimura E; Murase T; Nakamura T; Sakura M; Tateishi Y; Tsuda A; Kurajoh M; Mori K; Emoto M; Inaba M
    Sci Rep; 2017 Nov; 7(1):15416. PubMed ID: 29133805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Xanthine oxidoreductase activity in marathon runners: potential implications for marathon-induced acute kidney injury.
    Kosaki K; Kumamoto S; Tokinoya K; Yoshida Y; Sugaya T; Murase T; Akari S; Nakamura T; Nabekura Y; Takekoshi K; Maeda S
    J Appl Physiol (1985); 2022 Jul; 133(1):1-10. PubMed ID: 35608201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Annual change in plasma xanthine oxidoreductase activity is associated with changes in liver enzymes and body weight.
    Furuhashi M; Koyama M; Matsumoto M; Murase T; Nakamura T; Higashiura Y; Tanaka M; Moniwa N; Ohnishi H; Saitoh S; Shimamoto K; Miura T
    Endocr J; 2019 Sep; 66(9):777-786. PubMed ID: 31130575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Xanthine oxidoreductase and its inhibitors: relevance for gout.
    Day RO; Kamel B; Kannangara DR; Williams KM; Graham GG
    Clin Sci (Lond); 2016 Dec; 130(23):2167-2180. PubMed ID: 27798228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between plasma xanthine oxidoreductase activity and left ventricular ejection fraction and hypertrophy among cardiac patients.
    Fujimura Y; Yamauchi Y; Murase T; Nakamura T; Fujita SI; Fujisaka T; Ito T; Sohmiya K; Hoshiga M; Ishizaka N
    PLoS One; 2017; 12(8):e0182699. PubMed ID: 28797123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Newly Developed Method-Based Xanthine Oxidoreductase Activities in Various Human Liver Diseases.
    Sato K; Naganuma A; Nagashima T; Arai Y; Mikami Y; Nakajima Y; Kanayama Y; Murakami T; Uehara S; Uehara D; Yamazaki Y; Murase T; Nakamura T; Uraoka T
    Biomedicines; 2023 May; 11(5):. PubMed ID: 37239117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity.
    Furuhashi M
    Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E827-E834. PubMed ID: 32893671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of xanthine oxidoreductase forms: influence of reaction conditions.
    Martí R; Varela E; Pascual C; Segura RM
    Clin Chim Acta; 2001 Jan; 303(1-2):117-25. PubMed ID: 11163031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
    Chen C; Lü JM; Yao Q
    Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved method for measurement of human plasma xanthine oxidoreductase activity.
    Liu X; Lin WM; Yan XH; Chen XH; Hoidal JR; Xu P
    J Chromatogr B Analyt Technol Biomed Life Sci; 2003 Feb; 785(1):101-14. PubMed ID: 12535843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.